SCHEDULE 13G: Commodore Capital Discloses 9.9% Stake in SAB Biotherapeutics

Commodore Capital LP and its affiliates have reported a 9.9% beneficial ownership stake in SAB Biotherapeutics, Inc., primarily through converted Series B Preferred Stock.

Summary

• Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz collectively reported beneficial ownership of 4,522,977 shares of SAB Biotherapeutics, Inc. Common Stock.
• This represents 9.9% of the company's outstanding Common Stock, based on 45,108,294 shares reported by the Issuer.
• The ownership primarily consists of 4,401,500 shares issued to Commodore Capital Master LP following the conversion of Series B Convertible Preferred Stock, approved by stockholders on September 26, 2025.
• An additional 121,477 shares of Common Stock are issuable upon conversion of Series B Preferred Stock, subject to a 9.99% beneficial ownership limitation.
• The filing explicitly excludes 6,897,023 shares from Series B Preferred Stock conversion, 11,420,000 shares from enrollment warrants, and 5,710,000 shares from release warrants, all due to the 9.99% beneficial ownership limitation.
• The reporting persons share voting and dispositive power over the 4,522,977 shares.

Sentiment

Score: 6

Explanation: The filing reports a significant institutional ownership stake, which is generally a neutral to slightly positive signal as it indicates an investor's commitment. However, the presence of a substantial 'Ownership Blocker' on additional convertible shares introduces a potential future dilution risk, balancing the sentiment.

Positives

• A significant institutional investor, Commodore Capital, has taken a substantial 9.9% stake in SAB Biotherapeutics, indicating confidence in the company.
• The conversion of Series B Preferred Stock to Common Stock suggests a move towards a more straightforward capital structure for a portion of the investment.

Negatives

• The existence of a 9.99% beneficial ownership limitation (Ownership Blocker) prevents the immediate conversion and ownership of a larger number of shares (totaling 24,150,000 shares excluded), which could indicate potential dilution concerns if these blockers are removed or converted in the future.

Risks

• The beneficial ownership limitation (Ownership Blocker) of 9.99% restricts the immediate conversion of a significant number of additional shares (6,897,023 shares from Series B Preferred Stock, 11,420,000 shares from enrollment warrants, and 5,710,000 shares from release warrants). Future conversion of these shares could lead to substantial dilution for existing shareholders.

Future Outlook

This filing does not contain forward-looking statements or guidance from the issuer.

Industry Context

This filing indicates an institutional investor's significant stake in a biotechnology company, which is a common occurrence in the sector as investors seek exposure to potential growth. The conversion of preferred stock is a typical financing mechanism in biotech, often tied to specific milestones or approvals.

Stakeholder Impact

• Shareholders: The disclosure of a significant 9.9% stake by an institutional investor could be viewed positively, signaling confidence. However, the large number of shares subject to the 'Ownership Blocker' represents potential future dilution if converted, which could impact existing shareholders.

Key Dates

Recommendation

This filing is a factual disclosure of a significant ownership stake by an institutional investor. While a 9.9% stake can be seen as a vote of confidence, the presence of a substantial 'Ownership Blocker' on additional convertible shares introduces future dilution risk. Without further financial or operational details from SAB Biotherapeutics, a 'hold' recommendation is appropriate, acknowledging the institutional interest while remaining cautious about potential future dilution. Investors should monitor future filings for details on the conversion of the blocked shares and the company's performance.

Keywords

SAB Biotherapeutics, Commodore Capital, Beneficial Ownership, Schedule 13G, Common Stock, Series B Preferred Stock, Investment, Institutional Investor, Equity Stake, Biotechnology